SCHEDULE: ARCH Venture Funds Maintain Significant Sana Bio Stake

ARCH Venture Funds and affiliated entities report a combined 17.2% beneficial ownership in Sana Biotechnology, Inc., with Robert Nelsen holding 17.3%.

Summary

• ARCH Venture Funds and related entities collectively beneficially own 45,860,681 shares of Sana Biotechnology, Inc. common stock as of September 30, 2025.
• This ownership represents 17.2% of Sana Biotechnology's outstanding common stock.
• Robert Nelsen, an Investment Committee member, beneficially owns 46,093,125 shares, which includes 218,591 vested options, 1,353 fully vested restricted stock units, and 12,500 shares held by the Enzo Family Trust of 2015.
• Nelsen's total beneficial ownership accounts for 17.3% of the class.
• The reported percentages are based on 266,366,120 shares of common stock outstanding as of October 29, 2025, as disclosed in Sana Biotechnology's Form 10-Q filed on November 6, 2025.
• This document is an Amendment No. 4 to a Schedule 13G, indicating a passive investment position.

Sentiment

Score: 7

Explanation: The filing indicates continued strong institutional support from a major life sciences venture capital firm, which is generally positive for investor confidence. It's a routine ownership disclosure, so the sentiment is neutral to slightly positive due to the implied endorsement.

Positives

• Significant institutional ownership by ARCH Venture Partners, a prominent venture capital firm specializing in life sciences, signals strong confidence in Sana Biotechnology's long-term potential.
• The continued substantial stake suggests ongoing support and belief in the company's strategic direction from a key early investor.

Future Outlook

NA

Industry Context

ARCH Venture Partners is a leading venture capital firm focused on early-stage life science companies. Their substantial and continued stake in Sana Biotechnology, a company involved in advanced biotechnology, aligns with their investment strategy in innovative and potentially disruptive healthcare technologies. This indicates continued belief in Sana's position within the competitive biotech landscape and its potential for future growth.

Stakeholder Impact

• Shareholders: The continued significant ownership by ARCH Venture Partners may instill confidence among existing and potential shareholders, suggesting long-term institutional backing.
• Management: Strong institutional backing can provide stability and strategic guidance, potentially influencing management decisions and long-term planning.

Key Dates

Recommendation

This Schedule 13G filing primarily updates the beneficial ownership stake of ARCH Venture Partners in Sana Biotechnology. It confirms a substantial, continued investment by a prominent life sciences venture capital firm, which is a positive signal of long-term confidence. However, the filing itself does not contain new operational or financial data that would warrant a change in investment thesis. Therefore, maintaining a 'hold' position is appropriate, awaiting further fundamental news or financial reports from Sana Biotechnology.

Keywords

Sana Biotechnology, ARCH Venture Partners, Biotechnology, Institutional Ownership, SEC Filing, Schedule 13G, Common Stock, Venture Capital, SNY